London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.
The Madison, Wisconsin-based company is expanding its global operations with distribution deals in Turkey, South Africa, Russia, and Australia.
Lucigen has signed a global agreement with Illumina to be the sole distributor of Epicentre Technologies' genomics kits, enzymes, and ancillary reagents.
The exclusive agreement covers a portfolio of Epicentre products for transposomics, microarray analysis, and transcriptomics research.
The CSPro certification program is a two-step process that includes minimum data generation, data certification, and an on-site audit of a facility and its processes.
The firm presented results of a pre-clinical evaluation of the test and platform yesterday at the Next Generation Dx Summit in Washington, DC.
Lucigen's CEO said the agreement will provide researchers in India with his firm's technologies for use with NGS, cloning, and protein expression systems.
The proceeds will be used to fund development of a molecular diagnostics platform and for clinical trials to gain FDA approval for the platform.
NEW YORK (GenomeWeb) – Using fever to screen for Ebola casts a wide net, while standard RT-PCR requires many hours and expert technicians.
A majority of these assays use standard RT-PCR, but a few have novel methodologies that may help control the current outbreak in Africa, prevent an outbreak in the US, and possibly advance the field of molecular diagnostics.
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.